Quince Therapeutics, Inc.
QNCX$64M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO36 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
7wMarket Overview
Stock performance and key metrics
QNCX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
EryDex Low dose DSP
Nervous System Disease
Dexamethasone sodium phosphate
Ataxia Telangiectasia
Dex 21-P
Ulcerative Colitis
Dexamethasone
Nervous System Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EryDex Low dose DSP | Phase 3 | Nervous System Disease | - | - |
Dexamethasone sodium phosphate | Phase 3 | Ataxia Telangiectasia | - | - |
Dex 21-P | Phase 2 | Ulcerative Colitis | - | - |
Dexamethasone | Phase 2 | Nervous System Disorder | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply